The microbiome sequencing services market is projected to grow from USD 284 million in 2023 to USD 555 million by 2028 at a CAGR of 14.3%. Growth in this market is majorly driven by the increasing demand for metagenomic sequencing, the growing focus on human microbiome therapeutics development, and the high cost of advanced infrastructure for sequencing. However, a dearth of skilled personnel is expected to hinder the growth of this market during the forecast period.
The global microbiome sequencing services market is a fragmented market, with Charles River Laboratories (US), Eurofins Scientific (France), and BGI (China) emerging as the top leading players of the global market. Other prominent players/service providers include CosmosID (US), Microba (Australia), QIAGEN (Germany), Microbiome Insights (Canada), BaseClear (Netherlands), CD Genomics (US), Zymo Research (US), OraSure Technologies (US), MR DNA (US), Eremid Genomic Services (US), Clinical-Microbiomics A/S (Denmark), Novogene Co., Ltd. (China), EzBiome (US), Boster Biological Technology (US), Zifo (India), omics2view.consulting GbR (Germany), and Macrogen, Inc. (South Korea).
To know about the assumptions considered for the study download the pdf brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94324380
Charles River Laboratories (US)
CRL is the leading player in the microbiome sequencing services market. CRL offers customized and flexible sequencing solutions, supported by its comprehensive portfolio of drug discovery and research models and services. The company has focused on both organic and inorganic growth through expansions and partnerships. For instance, CRL partnered with Fios Genomics Ltd. (UK) to gain access to its bioinformatics solutions, helping CRL to develop a full spectrum of microbiome profiling/analysis services. In addition, the strong reach of CRL’s microbial detection product, Accugenix, is contributing to the company’s dominant position in the market.
Eurofins Scientific (France)
Eurofins Scientific has emerged as one of the leading players in the global microbiome sequencing services market. The company has focused on developing technology-enabled solutions to address its strong customer base. Additionally, investments in joint ventures and partnerships, and comprehensive microbiome sequencing solutions and processes are factors contributing to the growth of the company’s market share. The company provides drug discovery and development services to more than 220,000 customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians, hospitals and health systems, food & nutritional companies, and independent clinical laboratories.
Related Links
https://www.marketsandmarkets.com/Market-Reports/microbiome-sequencing-service-market-94324380.html
https://www.marketsandmarkets.com/ResearchInsight/microbiome-sequencing-service-market.asp
https://www.marketsandmarkets.com/PressReleases/microbiome-sequencing-service.asp
